Skip to content
Gian Lifecare logo

Gian Lifecare

542918 BSE
Price unavailable

Gian Lifecare (GIANLIFE) share price was ₹4.20 at the 28 Oct 2026 close; market capitalisation ₹4.35 Cr; sector Healthcare Services. The share price fell 66.8% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Dec 2025 quarter, revenue fell 29.6% year on year to ₹1.12 Cr and net profit was ₹0.10 Cr, against ₹0.35 Cr a year earlier (compared with Dec 2024). Promoters held 30.17% of Gian Lifecare in Mar 2026, down 1.92 percentage points from Dec 2025. Its Tapetide Score is 36/100 (Poor) as of 28 Oct 2026.

Close 28 Oct 2026 ₹4.20 −8.36 −66.56% 1Y

Key Fundamentals

MicrocapHealthcare ServicesHealthcare
Market Cap
₹4.35 Cr
EBITDA
₹1.20 Cr
Return on Equity
-0.19%
Debt to Equity
0.3
Book Value
₹18.15
EPS (TTM)
−₹0.92
52W High
₹13.23
52W Low
₹3.93

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Healthcare Services › Healthcare Service Provider

Dr Lal Pathlabs
₹1,905.4058.9231,982 Cr12.750.26%20.06%25.67%2,996 Cr545 Cr
Vijaya Diagnostic Centre
₹1,438.9078.9314,820 Cr15.480.14%18.07%19.22%879 Cr187 Cr
Metropolis Healthcare
₹549.1056.4311,388 Cr7.580.91%12.54%15.73%1,733 Cr203 Cr
Thyrocare Technologies
₹514.6546.458,191 Cr15.982.84%27.79%33.84%894 Cr176 Cr
Nephrocare Health Services
₹630.30150.436,338 Cr5.680.00%6.88%13.46%1,079 Cr85 Cr
Suraksha Diagnostic
₹318.3546.271,658 Cr6.770.16%12.90%14.70%329 Cr35 Cr
Krsnaa Diagnostics
₹496.0516.271,609 Cr1.640.40%10.35%10.64%862 Cr98 Cr
Gian Lifecare (this company)
——4 Cr0.230.00%-0.19%2.36%4 Cr-1 Cr
Median 8 companies₹549.1056.437,265 Cr7.180.21%12.72%15.22%887 Cr137 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

36 Poor
Overall score

Data confidence 91/100

Category scores

Quality Average 48
Returns, margins, earnings quality 22% weight
Valuation Average 53
Cheap vs sector & own history 24% weight
Growth Poor 1
Sales & profit trajectory 9% weight
Financial Health Poor 27
Solvency, leverage, coverage 9% weight
Momentum Poor 10
Trend strength, vol-adjusted 12% weight
Ownership Weak 40
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Stock is trading at 0.25 times its book value

Weaknesses

6
  • Company has low interest coverage ratio.
  • Promoter holding has decreased over last quarter: -1.92%
  • Promoter holding is low: 30.2%
  • Company has a low return on equity of 10.1% over last 3 years.
  • Promoters have pledged 65.1% of their holding.
  • Company has high debtors of 374 days.

Technical Indicators

Oscillators

Bearish

Bearish
2
Neutral
6
Bullish
1

Overall

Bearish

Bearish
12
Neutral
6
Bullish
1

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
-50% lower than 3Y

change over 1 year

Net Income Growth
-100% level than 3Y

change over 1 year

Cash Flow Change
-61.43%

change over 1 year

EBITDA Margin Change
-65.03%

change over 1 year Operating margin 22.32% · Dec 2025

Quarterly Results

Particulars Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales
5.09
1.55
2.43
2.3
3.79
4.6
1.98
1.95
1.59
1.11
0.87
0.66
1.12
Expenses
2.83
2.31
1.92
1.97
1.59
1.55
1.76
1.74
1.12
1.12
0.74
1.07
0.87
Operating Profit
2.26
-0.76
0.51
0.33
2.2
3.05
0.22
0.21
0.47
-0.01
0.13
-0.41
0.25
OPM %
44.4%
-49.03%
20.99%
14.35%
58.05%
66.3%
11.11%
10.77%
29.56%
-0.9%
14.94%
-62.12%
22.32%
Other Income
0.17
0.18
0.14
0.15
0.19
0.18
0.19
0.17
0.16
-0.24
0.15
0.09
0.09
Interest
0.12
0.11
0.12
0.11
0.14
0.1
0.14
0.12
0.12
0.13
0.09
0.12
0.15
Depreciation
0.14
0.12
0.13
0.13
0.16
0.11
0.12
0.12
0.12
0.27
0.11
0.11
0.11
PBT
2.17
-0.81
0.4
0.24
2.09
3.02
0.15
0.14
0.39
-0.65
0.08
-0.55
0.08
Tax %
13.82%
17.28%
35%
16.67%
25.36%
29.47%
40%
14.29%
10.26%
-7.69%
37.5%
-7.27%
-37.5%
Net Profit
1.86
-0.95
0.26
0.2
1.55
2.13
0.09
0.12
0.35
-0.6
0.05
-0.51
0.1
EPS (₹)
1.8
-0.92
0.25
0.19
1.5
2.06
0.09
0.12
0.34
-0.58
0.05
-0.49
0.1
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
15.45
11.41
12.78
5.94
3.76
Expenses
9.39
9.56
6.63
4.98
3.8
Operating Profit
6.06
1.85
6.15
0.96
-0.04
OPM %
39.22%
16.21%
48.12%
16.16%
-1.06%
Other Income
0.51
0.69
0.67
0.26
0.09
Interest
0.39
0.45
0.54
0.55
0.49
Depreciation
0.33
0.5
0.53
0.63
0.6
PBT
5.85
1.59
5.75
0.04
-1.04
Tax %
25.3%
33.33%
27.65%
200%
—
Net Profit
4.37
1.06
4.15
-0.04
-0.96
EPS (₹)
4.23
1.02
4.01
-0.04
-0.92
Div. Payout %
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
10.34
10.34
10.34
10.34
10.34
Reserves
3.69
4.78
8.93
8.89
8.43
Borrowings
2.03
4.57
4.88
5.84
5.73
Other Liabilities
7
8.56
8.48
10.86
9.65
Total Liabilities
23.06
28.25
32.63
35.93
34.15
Fixed Assets
3.5
4.62
5.07
4.45
4.22
CWIP
0.12
0.14
0.14
0.14
0.14
Investments
0
0
0
0
0
Other Assets
19.44
23.49
27.42
31.34
29.79
Total Assets
23.06
28.25
32.63
35.93
34.15
Figures in ₹ Crores

Cash Flow

Particulars Mar 2022Mar 2023Mar 2024Mar 2025
Operating
5.79
2.22
0.7
0.27
Investing
-4.12
-0.94
-0.32
0.25
Financing
0.67
-0.37
-0.16
0.45
Net Cash Flow
2.34
0.91
0.22
0.97
Free Cash Flow
4.83
0.59
-0.28
0.26
CFO/EBITDA
107
121
12
31
Figures in ₹ Crores

Ratios

Particulars Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
42.05
104
137
374
Cash Conversion Cycle
42.05
104
137
374
Working Capital Days
-31.66
-162
-81.4
-75.58
ROCE %
—
11.41%
28.7%
2.4%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Gian Lifecare insights

52 extracted metrics + investor summaries across FY19–FY26.

Shareholding Pattern

Govt.0.01%Public53.47%Others16.35%Promot.30.17%As ofMar 2026
65.08% of promoter holding pledged as of 14 Oct 2026

Documents

Frequently Asked Questions about Gian Lifecare

What does Gian Lifecare Ltd do?
Incorporated in 2018, Gian Lifecare Ltd is in the business of independent diagnostic/pathological laboratories[1]
Where is Gian Lifecare Ltd (GIANLIFE) listed?
Gian Lifecare Ltd trades under code 542918 on the BSE.
Which sector does Gian Lifecare Ltd belong to?
Gian Lifecare Ltd is classified under the Healthcare Services sector, in the Healthcare Service Provider industry.
What is the market capitalisation of Gian Lifecare Ltd?
Gian Lifecare Ltd has a market capitalisation of ₹4.35 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of Gian Lifecare Ltd?
Over the last 52 weeks Gian Lifecare Ltd has traded between ₹3.93 and ₹13.23 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Gian Lifecare Ltd?
Gian Lifecare Ltd reported a return on equity of -0.19%. Its debt-to-equity ratio is 0.30.

Company Information

Incorporated in 2018, Gian Lifecare Ltd is in the business of independent diagnostic/pathological laboratories[1]

Website gianpathlabs.com
Listed 2020-01-13
Face Value ₹ 10
Shares Outstanding 1,03,61,446

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/542918.md for Gian Lifecare Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month